Dr. Grey AI

Tirzepatide (Mounjaro/Zepbound)

Peptide

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It is a 39-amino-acid synthetic peptide based on the native GIP sequence with a C20 fatty diacid modification enabling once-weekly dosing. The SURPASS and SURMOUNT clinical trial programs demonstrated unprecedented efficacy for glycemic control and weight loss, with up to 22.5% body weight reduction.

Quick Answer

What it is

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It is a 39-amino-acid synthetic peptide based on the native GIP sequence with a C20 fatty diacid modification enabling once-weekly dosing.

Key findings

  • Grade A: Body Weight Reduction (Obesity)
  • Grade A: Weight Loss ≥5% Achievement (Obesity)
  • Grade A: Weight Loss ≥20% Achievement (Obesity)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Tirzepatide (Mounjaro/Zepbound)

Quick Facts: Tirzepatide (Mounjaro/Zepbound)

  • Best Evidence:Grade A
  • Conditions Studied:3
  • Research Outcomes:17
  • Grade A Findings:9
  • Grade B Findings:4
  • Key Effect:Obesity
A9
B4
C2
D2
3 conditions · 17 outcomes

Detailed Outcomes

|
A
Body Weight Reduction
SURMOUNT-1 showed 15-22.5% weight loss vs 3.1% placebo at 72 weeks. SURMOUNT-4 showed 20.9% weight loss maintained with continued treatment.
large↓Improves
A
Weight Loss ≥5% Achievement
SURMOUNT-1 showed 89-91% achieved ≥5% weight loss with 10-15mg tirzepatide vs 35% placebo.
large↑Worsens
A
Weight Loss ≥20% Achievement
SURMOUNT-1 showed 50-57% achieved ≥20% weight loss with 10-15mg tirzepatide, unprecedented for pharmacotherapy.
large↑Worsens
A
Obstructive Sleep Apnea Severity
SURMOUNT-OSA demonstrated significant reduction in sleep apnea severity with tirzepatide in participants with obesity.
large↓Improves
A
HbA1c Reduction
SURPASS trials showed HbA1c reductions of 1.87-2.58%. SURPASS-2 showed tirzepatide superior to semaglutide 1mg (2.0-2.3% vs 1.86% reduction).
large↓Improves
A
Glycemic Control (HbA1c <7%)
SURPASS-1 showed 87-92% reached HbA1c <7% vs 20% placebo. Up to 52% reached HbA1c <5.7% (normoglycemia).
large↑Worsens
A
Weight Loss in Diabetes
SURPASS trials showed 5.4-12.9 kg weight loss in T2DM patients. SURPASS-2 showed tirzepatide 15mg achieved nearly twice the weight loss of semaglutide 1mg.
large↓Improves
A
Beta-Cell Function
SURPASS-1 analysis showed tirzepatide improved markers of beta-cell function and insulin sensitivity as monotherapy.
moderate↑Improves
A
Fasting Plasma Glucose
SURPASS trials showed substantial reductions in fasting glucose across all dose levels compared to placebo and active comparators.
large↓Improves
B
Blood Glucose Control
29 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↓Improves
B
Safety/Tolerability
9 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
C
Liver Protection
3 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Cardiac Protection
3 human trials support this finding. Human clinical trial data available.
small↑Improves
D
Anti-Cancer Activity
2 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
small↑Improves
D
Neuroprotection
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
B
Cardiovascular Outcomes (MACE)
SURPASS-CVOT showed tirzepatide non-inferior to dulaglutide for MACE in patients with T2DM and established cardiovascular disease.
moderate↓Improves

Research Citations (51)

Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial
(2025)
PMID: 40365662
Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial
(2025)
PMID: 40545827
Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives.
(2025)
PMID: 40782123
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
(2025)
PMID: 40031941
Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.
(2025)
PMID: 39814031
Tirzepatide: a novel therapeutic approach for Alzheimer's disease.
(2025)
PMID: 40498212
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
(2025)
PMID: 39555826
The promise of tirzepatide: A narrative review of metabolic benefits.
(2025)
PMID: 40221292
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
(2024)
PMID: 38078870
Tirzepatide: A Review in Type 2 Diabetes
(2024)
PMID: 38388874

Related Peptides

Semaglutide (Ozempic/Wegovy)

Peptide

3 shared conditions · 17 outcomes

Semaglutide is a GLP-1 receptor agonist peptide approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). It is a 31-amino-acid peptide analog of human GLP-1 with 94% structural similarity but modified for extended half-life (approximately 1 week). The STEP, SUSTAIN, and SELECT clinical trial programs demonstrated consistent, substantial benefits for glycemic control, weight loss, and cardiovascular outcomes.